title: Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment.
authors.forename: N
authors.initials: N
authors.lastname: Funel
authors.forename: E
authors.initials: E
authors.lastname: Vasile
authors.forename: M
authors.initials: M
authors.lastname: Del Chiaro
authors.forename: U
authors.initials: U
authors.lastname: Boggi
authors.forename: A
authors.initials: A
authors.lastname: Falcone
authors.forename: D
authors.initials: D
authors.lastname: Campani
authors.forename: A
authors.initials: A
authors.lastname: Scarpa
authors.forename: E
authors.initials: E
authors.lastname: Giovannetti
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D066246:ErbB Receptors; D000093542:Gemcitabine